{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:00:22Z","timestamp":1788184822752,"version":"build-2803163510"},"reference-count":43,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hairy cell leukemia (HCL) remains an incurable disease. However, first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. Although there are excellent long-term data for intravenous application, similar data regarding subcutaneous administration are lacking. We therefore analyzed the long-term outcome of 3 prospective multicenter clinical trials on subcutaneous cladribine performed by the Swiss Group for Clinical Cancer Research (SAKK), which recruited 221 patients with classical HCL between 1993 and 2005. Median overall survival from start of treatment was not reached. Pretreatment anemia, higher Eastern Cooperative Oncology Group score, and higher age were associated with poorer overall survival in multivariable analysis, whereas early progression at 24 and 36 months had no significant impact on overall survival. Second-line treatment was necessary in 53 (23.7%) patients after a median of 5 (range, 0.2-20.4) years, and first retreatment was mainly monotherapy with cladribine (66%) or rituximab (15.1%) or a combination of these drugs (15.1%). A total of 44 (19.9%) patients developed second primary malignancies with a median time to occurrence of 5.7 (range, 0.01-17.5) years. Second primary malignancies were the main cause for death (14; 27.5%). Compared with a matched normal Swiss population, the incidence of second primary malignancies was not increased. However, survival of patients with HCL was slightly inferior by comparison (P = .036). In conclusion, the outcome of HCL patients treated with subcutaneous cladribine is excellent, and in most patients, 1 cycle of subcutaneous cladribine is sufficient for long-term disease control.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002160","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T17:50:38Z","timestamp":1597081838000},"page":"3699-3707","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-6454","authenticated-orcid":false,"given":"Rudolf","family":"Benz","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Kantonsspital Muensterlingen, Muensterlingen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelius","family":"Arn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kantonsspital Luzern, Luzern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-2988","authenticated-orcid":false,"given":"Martin","family":"Andres","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital Bern, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baumann","sequence":"additional","affiliation":[{"name":"Center for Laboratory Medicine St. Gallen, St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-2101","authenticated-orcid":false,"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital Bern, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Hitz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Zenhaeusern","sequence":"additional","affiliation":[{"name":"Department of Oncology Spitalzentrum Oberwallis, Brig, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-8104","authenticated-orcid":false,"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[{"name":"Hematology Division, University Hospital Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mey","sequence":"additional","affiliation":[{"name":"Oncology and Hematology, Kantonsspital Graubuenden, Graubuenden, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-3081","authenticated-orcid":false,"given":"Sabine","family":"Blum","sequence":"additional","affiliation":[{"name":"Service of Hematology, University Hospital Lausanne, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Oncology, Spital Thun, Thun, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"O'Meara Stern","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kantonsspital Neuchatel, Neuchatel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Cantoni","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transfusionmedicine, Kantonsspital Aarau, Aarau, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bargetzi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transfusionmedicine, Kantonsspital Aarau, Aarau, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bianchi-Papina","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lohri","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kantonsspital Baselland Liestal, Liestal, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Berardi","sequence":"additional","affiliation":[{"name":"Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3837-8477","authenticated-orcid":false,"given":"Anita","family":"Feller","sequence":"additional","affiliation":[{"name":"Foundation National Institute for Cancer Epidemiology and Registration, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-0637","authenticated-orcid":false,"given":"Georg","family":"Stussi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"issue":"12","key":"2020081311442623600_B1","first-page":"3605","article-title":"Epidemiology of hairy cell leukemia in Los Angeles County","volume":"50","author":"Bernstein","year":"1990","journal-title":"Cancer Res"},{"issue":"3","key":"2020081311442623600_B2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.thj.6200167","article-title":"Epidemiology of hairy cell leukemia in Iceland","volume":"3","author":"Kristinsson","year":"2002","journal-title":"Hematol J"},{"issue":"1","key":"2020081311442623600_B3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N Engl J Med"},{"issue":"8385","key":"2020081311442623600_B4","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(84)91491-0","article-title":"Complete remission in hairy cell leukaemia achieved with pentostatin","volume":"1","author":"Spiers","year":"1984","journal-title":"Lancet"},{"issue":"16","key":"2020081311442623600_B5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"N Engl J Med"},{"issue":"3","key":"2020081311442623600_B6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bjh.12490","article-title":"Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors","volume":"163","author":"Chandran","year":"2013","journal-title":"Br J Haematol"},{"key":"2020081311442623600_B7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2011.565093","article-title":"Long-term results for pentostatin and cladribine treatment of hairy cell leukemia","volume":"52","author":"Dearden","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020081311442623600_B8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020081311442623600_B9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.1995.13.4.989","article-title":"Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia","volume":"13","author":"Juliusson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020081311442623600_B10","first-page":"385","article-title":"Cellular pharmacokinetics of 2-chloro-2\u2032-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients","volume":"1","author":"Liliemark","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2020081311442623600_B11","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/sj.leu.2403418","article-title":"An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine","volume":"18","author":"Jehn","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"2020081311442623600_B12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2013-06-508754","article-title":"Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series","volume":"123","author":"Rosenberg","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020081311442623600_B13","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V88.6.1954.bloodjournal8861954","article-title":"Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience","volume":"88","author":"Tallman","year":"1996","journal-title":"Blood"},{"issue":"s","key":"2020081311442623600_B14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/10428194.2011.565842","article-title":"Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy","volume":"52","author":"Juliusson","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2020081311442623600_B15","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/annonc\/mdf272","article-title":"Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study","volume":"13","author":"von Rohr","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"2020081311442623600_B16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10428190802527681","article-title":"Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32\/95","volume":"50","author":"Zenh\u00e4usern","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020081311442623600_B17","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/10428190903131755","article-title":"Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32\/98)","volume":"50","author":"Zenh\u00e4usern","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020081311442623600_B18","first-page":"405","article-title":"Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia","volume":"1","year":"1987","journal-title":"Leukemia"},{"issue":"4","key":"2020081311442623600_B19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2307\/2529881","article-title":"Maximally selected chi square statistics","volume":"38","author":"Miller","year":"1982","journal-title":"Biometrics"},{"issue":"1","key":"2020081311442623600_B20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1536867X1501500112","article-title":"Estimating and modeling relative survival","volume":"15","author":"Dickman","year":"2015","journal-title":"Stata J"},{"issue":"6","key":"2020081311442623600_B21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"2020081311442623600_B22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2005-01-0173","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience","volume":"106","author":"Chadha","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2020081311442623600_B23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.beha.2015.10.021","article-title":"Hairy cell leukemia","volume":"28","author":"Dearden","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"2020081311442623600_B24","first-page":"309","article-title":"Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine","volume":"89","author":"Zinzani","year":"2004","journal-title":"Haematologica"},{"issue":"S1","key":"2020081311442623600_B25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hon.2594","article-title":"New treatment options in hairy cell leukemia with focus on BRAF inhibitors","volume":"37","author":"Falini","year":"2019","journal-title":"Hematol Oncol"},{"issue":"11","key":"2020081311442623600_B26","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.21447","article-title":"Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years","volume":"104","author":"Else","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"2020081311442623600_B27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5858\/2006-130-374-PPPOMR","article-title":"Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia","volume":"130","author":"Mhawech-Fauceglia","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2020081311442623600_B28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020081311442623600_B29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020081311442623600_B30","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.19.02250","article-title":"Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia","volume":"38","author":"Chihara","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020081311442623600_B31","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/cncr.23032","article-title":"The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent\/refractory hairy cell leukemia","volume":"110","author":"Else","year":"2007","journal-title":"Cancer"},{"issue":"21","key":"2020081311442623600_B32","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2020081311442623600_B33","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.leukres.2015.09.015","article-title":"Impact of telomere length on survival in classic and variant hairy cell leukemia","volume":"39","author":"Arons","year":"2015","journal-title":"Leuk Res"},{"issue":"6","key":"2020081311442623600_B34","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression","volume":"104","author":"Seymour","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2020081311442623600_B35","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2020081311442623600_B36","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020081311442623600_B37","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.1998.16.9.3007","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients","volume":"16","author":"Cheson","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020081311442623600_B38","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1997.15.3.1138","article-title":"Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up","volume":"15","author":"Hoffman","year":"1997","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020081311442623600_B39","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1182\/blood-2006-08-042929","article-title":"Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial","volume":"109","author":"Robak","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2020081311442623600_B40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnci\/djk030","article-title":"Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study","volume":"99","author":"Hisada","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2020081311442623600_B41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood.V92.4.1160","article-title":"Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience","volume":"92","author":"Au","year":"1998","journal-title":"Blood"},{"issue":"6","key":"2020081311442623600_B42","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2020081311442623600_B43","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.1997.15.5.1803","article-title":"Second cancer risk in hairy cell leukemia: analysis of 350 patients","volume":"15","author":"Kurzrock","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/15\/3699\/1755025\/advancesadv2020002160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/15\/3699\/1755025\/advancesadv2020002160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T03:38:54Z","timestamp":1616902734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/15\/3699\/461755\/Prospective-longterm-followup-after-firstline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":43,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002160","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]}}}